Leerink Partnrs Has Bearish Forecast for SPRY Q2 Earnings

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) – Leerink Partnrs reduced their Q2 2025 earnings estimates for shares of ARS Pharmaceuticals in a research note issued on Wednesday, May 14th. Leerink Partnrs analyst R. Ruiz now anticipates that the company will earn ($0.43) per share for the quarter, down from their prior forecast of ($0.37). The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.55) per share. Leerink Partnrs also issued estimates for ARS Pharmaceuticals’ Q3 2025 earnings at ($0.47) EPS, Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($1.50) EPS, FY2026 earnings at ($0.71) EPS, FY2027 earnings at $0.35 EPS and FY2028 earnings at $2.25 EPS.

A number of other equities analysts also recently commented on the company. Scotiabank began coverage on ARS Pharmaceuticals in a report on Friday, March 7th. They issued a “sector outperform” rating and a $30.00 price objective on the stock. Oppenheimer assumed coverage on shares of ARS Pharmaceuticals in a research report on Monday, February 10th. They set an “outperform” rating and a $40.00 price target on the stock. Finally, William Blair reiterated an “outperform” rating on shares of ARS Pharmaceuticals in a report on Monday, March 3rd. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, ARS Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $31.00.

ARS Pharmaceuticals Trading Up 0.5%

Shares of ARS Pharmaceuticals stock opened at $14.33 on Monday. The business’s fifty day moving average price is $13.43 and its 200 day moving average price is $12.87. ARS Pharmaceuticals has a twelve month low of $7.55 and a twelve month high of $18.51. The stock has a market capitalization of $1.41 billion, a P/E ratio of -28.10 and a beta of 0.84.

ARS Pharmaceuticals (NASDAQ:SPRY) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.35). The company had revenue of $7.97 million for the quarter, compared to analysts’ expectations of $7.48 million.

Hedge Funds Weigh In On ARS Pharmaceuticals

A number of institutional investors have recently made changes to their positions in SPRY. Alliancebernstein L.P. grew its position in shares of ARS Pharmaceuticals by 5,168.4% during the fourth quarter. Alliancebernstein L.P. now owns 3,880,734 shares of the company’s stock worth $40,942,000 after buying an additional 3,807,074 shares in the last quarter. MPM Bioimpact LLC acquired a new stake in ARS Pharmaceuticals in the first quarter valued at $16,519,000. Alyeska Investment Group L.P. boosted its stake in ARS Pharmaceuticals by 903.0% during the 4th quarter. Alyeska Investment Group L.P. now owns 1,253,724 shares of the company’s stock valued at $13,227,000 after acquiring an additional 1,128,724 shares during the last quarter. Cormorant Asset Management LP grew its holdings in ARS Pharmaceuticals by 220.0% during the 1st quarter. Cormorant Asset Management LP now owns 1,600,000 shares of the company’s stock worth $20,128,000 after acquiring an additional 1,100,000 shares in the last quarter. Finally, Aberdeen Group plc acquired a new position in ARS Pharmaceuticals during the 1st quarter worth $12,613,000. 68.16% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Laura Shawver sold 50,002 shares of the firm’s stock in a transaction dated Monday, April 7th. The stock was sold at an average price of $12.30, for a total transaction of $615,024.60. Following the completion of the sale, the director now directly owns 210,346 shares in the company, valued at $2,587,255.80. This trade represents a 19.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Eric Karas sold 10,000 shares of ARS Pharmaceuticals stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $14.00, for a total value of $140,000.00. Following the sale, the insider now directly owns 7,696 shares in the company, valued at approximately $107,744. The trade was a 56.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 109,602 shares of company stock worth $1,311,041 in the last 90 days. 33.50% of the stock is owned by company insiders.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.